Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

摘要: Background: Preplanned combined analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial North Central Cancer Treatment Group (NCCTG) (Alliance) N9831 Trial compared adjuvant chemotherapy with or without trastuzumab in women HER2-positive breast cancer. The initial results were reported 2005 updated early 2011 Methods: 4045 patients operable cancer enrolled to receive doxorubicin plus cyclophosphamide followed by paclitaxel both trials. definitive for OS will occur when 710 events have been reported. Results: Median time on study is 8 years. required number occurred be conducted end September 2012. Updated analyses disease free survival related subgroups also presented. Supported NCI grants U10-CA-12027, -69651, -37377, -69974, -44066, U24-CA-114732, CA25224; Research Foundation; Genentech 35–03 Citation Information: Res 2012;72(24 Suppl):Abstract nr S5-5.